BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD

Reuters03-26

March 26 (Reuters) - WAVE Life Sciences Ltd WVE.O:

WAVE LIFE SCIENCES ANNOUNCES POSITIVE DATA FROM FORWARD-53 CLINICAL TRIAL IN DMD INCLUDING SIGNIFICANT FUNCTIONAL BENEFIT AND REVERSAL OF MUSCLE DAMAGE AFTER 48 WEEKS OF DOSING WITH WVE-N531
WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS 3.8-SECOND IMPROVEMENT IN TIME-TO-RISE VERSUS. NATURAL HISTORY
WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS SIGNIFICANT REDUCTION IN MUSCLE FIBROSIS
WAVE LIFE SCIENCES LTD - WVE-N531 SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS
WAVE LIFE SCIENCES LTD - TO FILE NDA FOR WVE-N531 IN 2026 FOR ACCELERATED APPROVAL
WAVE LIFE SCIENCES LTD: WVE-N531 REMAINS SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS
WAVE LIFE SCIENCES LTD - TO FILE CTAS IN 2026 FOR MULTIPLE DMD CANDIDATES

Source text: ID:nGNX5PK42X

Further company coverage: WVE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522876098?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-26 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522876098","market":"nz","top_or_hot":-1,"title":"BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD</title></head><body><p><span>March 26 (Reuters)</span><span> - </span>WAVE Life Sciences Ltd <span>WVE.O</span>:</p><ul><li><p>WAVE LIFE SCIENCES ANNOUNCES POSITIVE DATA FROM FORWARD-53 CLINICAL TRIAL IN DMD INCLUDING SIGNIFICANT FUNCTIONAL BENEFIT AND REVERSAL OF MUSCLE DAMAGE AFTER 48 WEEKS OF DOSING WITH WVE-N531</p></li><li><p>WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS 3.8-SECOND IMPROVEMENT IN TIME-TO-RISE VERSUS. NATURAL HISTORY</p></li><li><p>WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS SIGNIFICANT REDUCTION IN MUSCLE FIBROSIS</p></li><li><p>WAVE LIFE SCIENCES LTD - WVE-N531 SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li><li><p>WAVE LIFE SCIENCES LTD - TO FILE NDA FOR WVE-N531 IN 2026 FOR ACCELERATED APPROVAL</p></li><li><p>WAVE LIFE SCIENCES LTD: WVE-N531 REMAINS SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li><li><p>WAVE LIFE SCIENCES LTD - TO FILE CTAS IN 2026 FOR MULTIPLE DMD CANDIDATES</p></li></ul><p>Source text: <span>ID:nGNX5PK42X</span></p><p>Further company coverage: <span>WVE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-26 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD</title></head><body><p><span>March 26 (Reuters)</span><span> - </span>WAVE Life Sciences Ltd <span>WVE.O</span>:</p><ul><li><p>WAVE LIFE SCIENCES ANNOUNCES POSITIVE DATA FROM FORWARD-53 CLINICAL TRIAL IN DMD INCLUDING SIGNIFICANT FUNCTIONAL BENEFIT AND REVERSAL OF MUSCLE DAMAGE AFTER 48 WEEKS OF DOSING WITH WVE-N531</p></li><li><p>WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS 3.8-SECOND IMPROVEMENT IN TIME-TO-RISE VERSUS. NATURAL HISTORY</p></li><li><p>WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS SIGNIFICANT REDUCTION IN MUSCLE FIBROSIS</p></li><li><p>WAVE LIFE SCIENCES LTD - WVE-N531 SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li><li><p>WAVE LIFE SCIENCES LTD - TO FILE NDA FOR WVE-N531 IN 2026 FOR ACCELERATED APPROVAL</p></li><li><p>WAVE LIFE SCIENCES LTD: WVE-N531 REMAINS SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS</p></li><li><p>WAVE LIFE SCIENCES LTD - TO FILE CTAS IN 2026 FOR MULTIPLE DMD CANDIDATES</p></li></ul><p>Source text: <span>ID:nGNX5PK42X</span></p><p>Further company coverage: <span>WVE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nTUA33G53J:1","article_id":"2522876098","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522876098","pubTimestamp":1742989262,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMDMarch 26 (Reuters) - WAVE Life Sciences Ltd WVE.O:WAVE LIFE SCIENCES ANNOUNCES POSITIVE DATA FROM FORWARD-53 CLINI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","WVE":"Wave Life Sciences Pte. Ltd"},"translate_title":"BRIEF-Wave Life Sciences宣布DMD FORWARD-53临床试验的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WVE":0.9},"content_text":"BRIEF-Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMDMarch 26 (Reuters) - WAVE Life Sciences Ltd WVE.O:WAVE LIFE SCIENCES ANNOUNCES POSITIVE DATA FROM FORWARD-53 CLINICAL TRIAL IN DMD INCLUDING SIGNIFICANT FUNCTIONAL BENEFIT AND REVERSAL OF MUSCLE DAMAGE AFTER 48 WEEKS OF DOSING WITH WVE-N531WAVE LIFE SCIENCES LTD - WVE-N531 SHOWS 3.8-SECOND IMPROVEMENT IN TIME-TO-RISE VERSUS. NATURAL HISTORYWAVE LIFE SCIENCES LTD - WVE-N531 SHOWS SIGNIFICANT REDUCTION IN MUSCLE FIBROSISWAVE LIFE SCIENCES LTD - WVE-N531 SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTSWAVE LIFE SCIENCES LTD - TO FILE NDA FOR WVE-N531 IN 2026 FOR ACCELERATED APPROVALWAVE LIFE SCIENCES LTD: WVE-N531 REMAINS SAFE AND WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTSWAVE LIFE SCIENCES LTD - TO FILE CTAS IN 2026 FOR MULTIPLE DMD CANDIDATESSource text: ID:nGNX5PK42XFurther company coverage: WVE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522876098"}